Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Canadian veterinary journal = La revue veterinaire canadienne

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 23997262PMCID PMC3573631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical implications of measurement of plasma atrial natriuretic peptide concentration in dogs with spontaneous heart disease.

  2011cited by this paper
• Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.

  2011cited by this paper
• Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.

  2010influential reference
• Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

  2010cited by this paper
• Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs.

  2010cited by this paper
• N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease.

  2010cited by this paper
• Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease.

  2009cited by this paper
• Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.

  2009cited by this paper
• Tyrosine kinase inhibitors in veterinary medicine.

  2009cited by this paper
• Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.

  2009cited by this paper
• Molecular pathogenesis of pulmonary arterial hypertension.

  2008cited by this paper
• Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

  2008influential reference
• Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.

  2008cited by this paper
• Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

  2008cited by this paper
• Molecular pathogenesis of pulmonary arterial hypertension.

  2008cited by this paper
• Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease.

  2008cited by this paper
• Quantification of mitral valve regurgitation in dogs with degenerative mitral valve disease by use of the proximal isovelocity surface area method.

  2007cited by this paper
• IMATINIB MESYLATE INHIBITS FIBROGENESIS IN ASBESTOS-INDUCED INTERSTITIAL PNEUMONIA

  2007cited by this paper
• Treatment of pulmonary arterial hypertension.

  2006cited by this paper
• Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs.

  2006cited by this paper
• Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.

  2006cited by this paper
• Reduced exercise capacity in a mouse model of asthma

  2006cited by this paper
• Long term imatinib treatment in pulmonary arterial hypertension.

  2006cited by this paper
• Prednisolone Inhibits Proliferation of Cultured Pulmonary Artery Smooth Muscle Cells of Patients With Idiopathic Pulmonary Arterial Hypertension

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• PDGF signaling in pulmonary arterial hypertension.

  2005cited by this paper
• Imatinib for the treatment of pulmonary arterial hypertension.

  2005cited by this paper
• Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension.

  2004cited by this paper
• Treatment of pulmonary arterial hypertension.

  2004cited by this paper
• Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease.

  2003cited by this paper
• Textbook of Respiratory Disease in Dogs and Cats

  2003cited by this paper
• Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.

  2003cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996.

  1999cited by this paper
• Right ventricular stiffness measured by a new method without volume estimation in coronary artery disease.

  1996cited by this paper
• Myocardial velocity gradient as a new indicator of regional left ventricular contraction: detection by a two-dimensional tissue Doppler imaging technique.

  1995cited by this paper
• New non-invasive index for combined systolic and diastolic ventricular function.

  1995cited by this paper
• Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure.

  1994cited by this paper
• Elevated pulmonary artery pressure. An independent predictor of mortality.

  1991cited by this paper
• Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.

  1989cited by this paper
• Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements

  1978cited by this paper

• Tyrosine kinase inhibitors in canine solid tumours: a systematic review of indications, response and safety

  2025influential citation
• Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. From In vitro to In vivo

  2024cites this paper
• Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine.

  2023cites this paper
• Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020

  2022cites this paper
• Pulmonary hypertension in dogs: an overview

  2021cites this paper
• Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study

  2020cites this paper
• ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs

  2020influential citation
• Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.

  2020cites this paper
• Short-term effects of sildenafil in the treatment of dogs with pulmonary hypertension secondary to degenerative mitral valve disease

  2020cites this paper
• Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.

  2019cites this paper
• Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.

  2018cites this paper
• Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.

  2018cites this paper
• Pulmonary Hypertension

  2018cites this paper
• Long-term effect of low-dose imatinib therapy for pulmonary hypertension due to chronic degenerative mitral valve disease in six dogs

  2018cites this paper
• Pulmonary Hypertension in the Dog

  2016cites this paper
• Heart rate, rhythm, and contractility

  2016cites this paper
• Dysregulation of tyrosine kinases and use of imatinib in small animal practice.

  2015cites this paper
• Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment

  2014cites this paper